Translating biomedical discoveries into real-world applications is essential to improving human health. It’s a complex process that can result in delays of years or decades before improved patient outcomes result from discoveries in biomedical research – and NCATS wants solutions. NCATS’ (the ITM’s parent organization) spurs the development, demonstration, and dissemination of innovations across the translational science spectrum to turn discoveries from the laboratory into tangible benefits to human health. NCATS’s Clinical and Translational Science Award (CTSA) hubs, like the ITM, promote advances in translational research and training at participating institutions.
This funding opportunity funds up to $275,000 to new exploratory and developmental research projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on translational science. This grant will enable collaborative teams of investigators from at least two different CTSA institutions to address translational science questions. Collaborations that bring together approaches from different scientific disciplines are encouraged.
CHeSS, an ITM partner, is accepting applications for its Summer Program in Outcomes Research Training (SPORT) program, which provides an introduction to outcomes research for fellows and junior faculty, including coursework in health services research, biostatistics, research methods, and clinical epidemiology. The program also offers participants opportunities to develop a research proposal that could form the basis of an NIH or other career development award, and several SPORT courses are led by ITM investigators. Earn up to $3,000 to participate in SPORT.
2017 Program Dates: July 10 – Aug. 25, 2017
The NIH’s Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) provide up to $1 million over two years for small businesses and research organizations whose work in any biomedical or behavioral research area falls within the NIH’s mission to improve human health. NCATS small business funding is designed specifically to transform the translational science process so that new treatments and cures for disease can be delivered to patients more efficiently.
This funding opportunity accepts applications for a Clinical and Translational Science Award (CTSA) Program Data to Health Coordination Center that will support the activities of the CTSA Program in using data to translate discoveries to health benefit. It will provide up to $5 million over five years for projects that discover, develop, and disseminate innovation in informatics tools, standards, methods, and processes that will eventually benefit human health.
Source: NIH NCATS
NCATS will fund up to $400,000 for projects that develop 3D-bioprinted tissue models for drug discovery, including efficacy studies and toxicology research through a collaborative arrangement between the 3-D Bioprinting Program at NCATS and other scientists.
NCATS scientists will provide expertise for 3-D bioprinting, assay development, and drug screening stages of the projects. Other investigators will provide appropriate cell resources, disease expertise, and model validation to perform drug screening of bioprinted materials.
Source: NIH NCATS
The NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules program supports partnerships between pharmaceutical companies and the biomedical research community to advance therapeutics development. This innovative program matches researchers with pharmaceutical industry resources to test ideas for new therapeutic uses with the ultimate goal of identifying promising new treatments for patients.
Access Pfizer’s drug development expertise, publishing rights and its Centers for Therapeutic Innovation (CTI) foundation partners through research. The CTI and NIH are now accepting proposals for collaborative projects that focus on translational therapeutic drug targets.
Pfizer’s CTI pairs NIH intramural researchers with Pfizer scientists to pursue scientific and medical advances through joint research and development projects. The CTI model is the first NIH-wide biologics initiative with a pharmaceutical partner that NCATS coordinates on behalf of all NIH intramural researchers. The goal of the program is to identify biologic compounds with activity in a pathway or target of interest to an NIH intramural researcher and to Pfizer. Together, the scientific team works to move these compounds through laboratory testing and into clinical evaluation.
The NIH’s National Cancer Institute (the NIH is the parent organization of the ITM) will fund $4 million to approximately 10 exploratory projects that develop or validate emerging technologies that contribute to targeting, probing, or assessing molecular and cellular features of cancer biology. Projects should show potential to improve cancer biology research, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities.
Source: National Cancer Institute
The NIH’s National Cancer Institute (the NIH is the parent organization of the ITM) will fund $4 million to approximately 10 exploratory projects focused on the inception and early-stage development of innovative molecular and cellular analysis technologies. Projects should show potential to improve cancer biology research, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities.
Source: National Cancer Institute